Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:57:30 EDT Wed 17 Apr 2024
Enter Symbol
or Name
USA
CA



Q:CLDX - CELLDEX THERAPEUTICS INC - http://www.celldextherapeutics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CLDX - Q0.138.06·58.566.539.63+1.032.7954.937,4407,07139.01  40.45  38.6753.18  22.1117:17:5108:0115 min RT 2¢

Recent Trades - Last 10 of 7071
Time ETExPriceChangeVolume
17:17:51Q41.482.881
17:17:21Q39.631.0345,937
16:20:00Q39.631.0342
16:01:31Q39.631.0389
16:01:25Q39.631.0374
16:01:03Q39.631.031,691
16:00:59Q39.631.031,280
16:00:56Q39.631.031,355
16:00:53Q39.631.03198
16:00:12Q39.631.038,314

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-17 08:01U:CLDXNews ReleaseCelldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
2024-03-08 07:00U:CLDXNews ReleaseCelldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
2024-03-05 10:30U:CLDXNews ReleaseCelldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference
2024-03-05 10:11U:CLDXNews ReleaseCelldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
2024-02-29 21:15U:CLDXNews ReleaseCelldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock
2024-02-28 16:01U:CLDXNews ReleaseCelldex Therapeutics Announces Proposed Public Offering of Common Stock
2024-02-26 07:01U:CLDXNews ReleaseCelldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
2024-02-24 14:05U:CLDXNews ReleaseCelldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
2024-02-06 16:01U:CLDXNews ReleaseCelldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
2024-02-05 08:01U:CLDXNews ReleaseCelldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024
2023-11-27 16:15U:CLDXNews ReleaseCelldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference
2023-11-07 23:15U:CLDXNews ReleaseCelldex Therapeutics Announces Pricing of Public Offering of Common Stock
2023-11-07 16:01U:CLDXNews ReleaseCelldex Therapeutics Announces Proposed Public Offering of Common Stock
2023-11-06 06:30U:CLDXNews ReleaseCelldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
2023-11-05 15:00U:CLDXNews ReleaseCelldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg Barzolvolimab
2023-11-02 16:01U:CLDXNews ReleaseCelldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
2023-09-26 07:01U:CLDXNews ReleaseCelldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Prurigo Nodularis at 12th World Congress on Itch (WCI) 2023
2023-09-25 08:31U:CLDXNews ReleaseCelldex Therapeutics to Present at Cantor Global Healthcare Conference
2023-08-08 16:01U:CLDXNews ReleaseCelldex Reports Second Quarter 2023 Financial Results and Provides Corporate Update
2023-07-11 08:01U:CLDXNews ReleaseCelldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria